Anti‐IL‐7 receptor α monoclonal antibody (GSK2618960) in healthy subjects – a randomized, double‐blind, placebo‐controlled study

• Published in: British journal of clinical pharmacology Vol. 85; no. 2; pp. 304 - 315
• Main Authors: Ellis, Joanne, Maurik, Andre, Fortunato, Lea, Gisbert, Sophie, Chen, Keguan, Schwartz, Ann, McHugh, Simon, Want, Andrew, Santos Franco, Sara, Oliveira, Joao‐Joaquim, Price, Jeffrey, Coles, Alasdair, Brown, Kim, Su, Donggang, Craigen, Jenny L., Yang, Jiansong, Brett, Sara, Davis, Bill, Cheriyan, Joseph, Kousin‐Ezewu, Onajite, Gray, Frank, Thompson, Paul W., Fernando, Disala
• Format: Journal Article
• Language: English
• Published: England John Wiley and Sons Inc 01.02.2019
• Subjects: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized - adverse effects; Antibodies, Monoclonal, Humanized - pharmacokinetics; Antibodies, Monoclonal, Humanized - pharmacology; Antibodies, Monoclonal, Humanized - therapeutic use; Autoimmune Diseases - drug therapy; Autoimmune Diseases - immunology; Double-Blind Method; drug safety; Female; Half-Life; Healthy Volunteers; Humans; immunology; Infusions, Intravenous; Interleukin-7 Receptor alpha Subunit - antagonists & inhibitors; Interleukin-7 Receptor alpha Subunit - immunology; Male; Middle Aged; monoclonal antibodies; Original; pharmacodynamics; pharmacokinetics; Placebos - administration & dosage; Placebos - adverse effects; T-Lymphocytes - drug effects; T-Lymphocytes - immunology; T-Lymphocytes - metabolism; Young Adult; pharmacokinetics; immunology; pharmacodynamics; drug safety; monoclonal antibodies

Aim Interleukin (IL)‐7 signalling modulates T cell activity and is implicated in numerous autoimmune diseases. The present study investigated the safety, pharmacokinetics, target engagement, pharmacodynamics and immunogenicity of GSK2618960, an IL‐7 receptor‐α subunit (CD127) monoclonal antibody. Me...